CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CDNA is not a strong buy right now for a beginner long-term investor with $50,000-$100,000. The stock has constructive longer-term trend support from bullish moving averages and strong revenue growth, but the current setup is mixed: momentum is not confirming, there is no AI Stock Picker or SwingMax buy signal, and the short-term price action has been choppy. Given the user's impatient profile and desire to act now rather than wait for a better entry, the best direct call is to hold rather than buy today.
The technical picture is mildly bullish but not decisive. CDNA is trading above key moving averages with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. However, MACD histogram is slightly negative and contracting, showing momentum has weakened. RSI at 60.4 is neutral-to-slightly positive, not overbought, but also not a clear breakout signal. Price is near the pivot at 20.84 and below resistance at 22.75, so upside confirmation has not yet been proven. The recent pattern stats also lean slightly weak over the next day and month.
["Q1 revenue grew 38.99% YoY to $117.7M, showing strong top-line acceleration.", "Gross margin improved to 71.43%, indicating better business quality and operating leverage.", "BTIG raised its price target to $28 from $26 and maintained a Buy rating.", "Analyst commentary highlights upside from the Naveris acquisition and potential to exceed the 2027 revenue target.", "Options positioning is moderately bullish with a put-call open interest ratio of 0.56.", "No recent negative news in the last week."]
["No AI Stock Picker signal today.", "No SwingMax signal recently.", "MACD remains below zero, so momentum is not fully confirmed.", "Net income dropped to 0 and EPS declined sharply year over year.", "No recent news catalysts in the past week.", "Hedge funds and insiders show neutral activity, with no meaningful accumulation signal.", "No congress trading data is available."]
Latest quarter: Q1 2026. Revenue increased to $117.7M, up 38.99% YoY, which is a strong growth sign. Gross margin expanded to 71.43%, also positive. However, net income fell to 0 and EPS declined to 0.05, indicating profitability remains uneven despite revenue growth. Overall, the quarter shows strong growth trends but not yet clean earnings quality.
Analyst sentiment is positive and improving. BTIG raised its price target twice recently, from $25 to $26 and then to $28, while keeping a Buy rating. The latest note was especially upbeat, citing strong Q1 updates, the Naveris acquisition, and the expectation that CareDx can exceed its 2027 revenue target. Wall Street pros are constructive on growth and strategy, but the lack of broad consensus improvement and neutral insider/hedge fund activity keeps the view from becoming fully compelling.
